Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Thiazolidinediones398 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A37463 | 15625656 | Clin Gastroenterol Hepatol | A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. | 2004 | Details |
| A37472 | 15605307 | Semin Liver Dis | Hepatotoxicity of drugs used for treatment of obesity and its comorbidities. | 2004 | Details |
| A37543 | 15457967 | Ther Umsch | [Alcoholic and non-alcoholic steatohepatitis]. | 2004 | Details |
| A37568 | 15343508 | Hum Pathol | Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. | 2004 | Details |
| A37753 | 14752837 | Hepatology | A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. | 2004 | Details |
| A37835 | 14512888 | Hepatology | Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. | 2003 | Details |
| A37963 | 12663234 | J Hepatol | Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. | 2003 | Details |
| A38179 | 11965828 | Int J Clin Pract Suppl | Thiazolidinedione hepatotoxicity: a class effect? | 2000 | Details |
| A38390 | 11374713 | Am J Gastroenterol | Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. | 2001 | Details |
| A38442 | 11232700 | Am J Gastroenterol | A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. | 2001 | Details |
| A44385 | 28744408 | Am J Cancer Res | The role of thiazolidinediones in hepatocellular carcinoma risk reduction: a population-based cohort study in Taiwan. | 2017 | Details |
| A44389 | 28736228 | Biochim Biophys Acta Gen Subj | DBZ is a putative PPARγ agonist that prevents high fat diet-induced obesity, insulin resistance and gut dysbiosis. | 2017 | Details |
| A44398 | 28707804 | Aliment Pharmacol Ther | Letter: clinical response to pioglitazone in nonalcoholic steatohepatitis [NASH] treatment-use of pharmacokinetic surrogate. | 2017 | Details |
| A44409 | 28692223 | Rev Med Suisse | 2016 | Details | |
| A44410 | 28692197 | J Gastroenterol Hepatol | The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. | 2018 | Details |
| A44465 | 28539218 | Bioorg Med Chem Lett | Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists. | 2017 | Details |
| A44496 | 28468762 | Gut | Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus-authors' response. | 2017 | Details |
| A44501 | 28459036 | Indian J Endocrinol Metab | Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment. | 2020 | Details |
| A44512 | 28408383 | Gut | Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus. | 2017 | Details |
| A44553 | 28241265 | JAMA Intern Med | The Role of Pioglitazone in the Management of Nonalcoholic Steatohepatitis: Are We There Yet? | 2017 | Details |
| A44567 | 28166556 | Ann Intern Med | Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis. | 2017 | Details |
| A44568 | 28166555 | Ann Intern Med | Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis. | 2017 | Details |
| A44569 | 28166554 | Ann Intern Med | Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis. | 2017 | Details |
| A44629 | 27880988 | Hepatology | Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: New evidence, new challenges. | 2017 | Details |
| A44718 | 27594084 | Metabolism | Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonists. | 2016 | Details |
| A44721 | 29737646 | Diabetes Self Manag | THE HEPATITIS/DIABETES CONNECTION The Effect of Hep C cures on Type 2 diabetes still unknown. | 2016 | Details |
| A44781 | 27322943 | Ann Intern Med | Pioglitazone for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes. | 2016 | Details |
| A44782 | 27322890 | Ann Intern Med | Pioglitazone: An Addition to Our Toolbox for Patients With Diabetes and Nonalcoholic Steatohepatitis? | 2016 | Details |
| A44821 | 27181498 | J Diabetes Investig | Managing non-alcoholic fatty liver disease in diabetes: Challenges and opportunities. | 2016 | Details |
| A44858 | 27053230 | Diabetologia | EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. | 2016 | Details |
| A45611 | 23680744 | Hosp Pract (1995) | Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. | 2013 | Details |
| A45679 | 23304111 | PPAR Res | Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity. | 2012 | Details |
| A45779 | 22801247 | J Investig Med | Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes. | 2012 | Details |
| A45786 | 22751293 | Pol Arch Med Wewn | Comment on "Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease". | 2012 | Details |
| A45813 | 22612529 | J Vet Pharmacol Ther | Pharmacokinetics of pioglitazone in lean and obese cats. | 2012 | Details |
| A45830 | 22488764 | Hepatology | The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. | 2012 | Details |
| A45938 | 21953015 | Hepatology | Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials? | 2011 | Details |
| A46031 | 21480350 | Hepatology | Insulin sensitizers in nonalcoholic steatohepatitis. | 2011 | Details |
| A46100 | 21105109 | Hepatology | Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues. | 2010 | Details |
| A46410 | 21180527 | Therap Adv Gastroenterol | Treatment options for nonalcoholic Fatty liver disease. | 2008 | Details |
| A46492 | 18277910 | J Clin Gastroenterol | Therapy for nonalcoholic fatty liver disease. | 2008 | Details |
| A46520 | 18046722 | Hepatology | Effects of rosiglitazone on methionine-choline deficient diet-induced nonalcoholic steatohepatitis. | 2007 | Details |
| A46587 | 17429734 | Dig Dis Sci | The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease. | 2007 | Details |
| A46603 | 17354303 | N Engl J Med | Pioglitazone in nonalcoholic steatohepatitis. | 2007 | Details |
| A46645 | 16932311 | Nat Clin Pract Endocrinol Metab | Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance. | 2006 | Details |
| A46690 | 16510031 | Curr Gastroenterol Rep | New treatments for nonalcoholic fatty liver disease. | 2006 | Details |
| A46691 | 16493965 | Rev Med Suisse | [Hepatology]. | 2006 | Details |
| A46734 | 16098839 | Am J Cardiol | Management of dyslipidemia in patients with complicated metabolic syndrome. | 2005 | Details |
| A46743 | 15989845 | Med Clin (Barc) | [Medical management of primary nonalcoholic fatty liver disease]. | 2005 | Details |
| A46781 | 15611492 | Ann Intern Med | Narrative review: hepatobiliary disease in type 2 diabetes mellitus. | 2004 | Details |
| A46788 | 15547646 | Angiology | Prevention and treatment of the metabolic syndrome. | 2005 | Details |
| A46802 | 15262299 | Endocrinol Metab Clin North Am | Glitazones and the management of insulin resistance: what they do and how might they be used. | 2004 | Details |
| A47770 | 32213649 | Endocrinol Diabetes Metab Case Rep | The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide. | 2020 | Details |
| A47972 | 27765759 | Am J Physiol Gastrointest Liver Physiol | Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy. | 2016 | Details |
| A48006 | 26781175 | Mol Med Rep | TLR4‑dependent signaling pathway modulation: A novel mechanism by which pioglitazone protects against nutritional fibrotic steatohepatitis in mice. | 2016 | Details |
| A48117 | 22699820 | Cell Mol Life Sci | Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside. | 2012 | Details |
| A48139 | 21800342 | Hepatology | Targeting the renin-angiotensin system: potential beneficial effects of the angiotensin II receptor blockers in patients with nonalcoholic steatohepatitis. | 2011 | Details |
| A48192 | 20101743 | Hepatology | Thiazolidinedione therapy for nonalcoholic steatohepatitis: go, stop, or proceed with caution? | 2010 | Details |
| A48238 | 19013165 | Gastroenterology | Rosiglitazone for nonalcoholic steatohepatitis. | 2008 | Details |
| A48276 | 17661403 | Hepatology | Divergent effects of peroxisome proliferator-activated receptor-gamma ligands in human and mouse nonalcoholic steatohepatitis. | 2007 | Details |
| A48287 | 17354302 | N Engl J Med | Pioglitazone in nonalcoholic steatohepatitis. | 2007 | Details |
| A48288 | 17347462 | N Engl J Med | Pioglitazone in nonalcoholic steatohepatitis. | 2007 | Details |
| A48294 | 17135591 | N Engl J Med | Thiazolidinediones for nonalcoholic steatohepatitis--promising but not ready for prime time. | 2006 | Details |
| A48295 | 17135584 | N Engl J Med | A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. | 2006 | Details |
| A48297 | 17038787 | Nihon Yakurigaku Zasshi | [PPAR gamma ligand pioglitazone as a therapeutic strategy in nonalcoholic steatohepatitis (NASH)]. | 2006 | Details |
| A48341 | 16128278 | Pol Arch Med Wewn | [Effect of high-fat diet, rosiglitazone on lipid profile, insulin resistance and liver steatosis development]. | 2005 | Details |
| A48351 | 15625648 | Clin Gastroenterol Hepatol | Treatment of nonalcoholic steatohepatitis: antioxidants or insulin sensitizers? | 2004 | Details |
| A48369 | 14720447 | Curr Gastroenterol Rep | Treatment of nonalcoholic steatohepatitis. | 2004 | Details |
| A48392 | 12663460 | Diabetes | Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. | 2003 | Details |
| A48429 | 11232664 | Am J Gastroenterol | Insulin resistance and nonalcoholic steatohepatitis: fat or fiction? | 2001 | Details |
| A49027 | 20969493 | Scand J Gastroenterol | Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice. | 2010 | Details |
| A49080 | 18752754 | Zhonghua Gan Zang Bing Za Zhi | [Effect of rosiglitazone in non-alcoholic steatohepatitis associated liver fibrosis]. | 2008 | Details |
| A49096 | 17926479 | Ter Arkh | [Pathogenetic treatment of non-alcoholic steatohepatitis: arguments, efficacy, safety]. | 2007 | Details |
| A49192 | 14585066 | Expert Opin Drug Saf | Hepatotoxicity of thiazolidinediones. | 2003 | Details |
| A49394 | 35765391 | Cureus | The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review. | 2022 | Details |
| A50622 | 35323681 | Metabolites | Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH. | 2022 | Details |
| A52269 | 29453696 | Heart Fail Rev | Interrelationship between diabetes mellitus and heart failure: the role of peroxisome proliferator-activated receptors in left ventricle performance. | 2018 | Details |
| A52702 | 23303913 | Physiol Rev | Pathophysiology of human visceral obesity: an update. | 2013 | Details |
| A52751 | 22471957 | Cardiovasc Hematol Agents Med Chem | PPAR- γ agonist in treatment of diabetes: cardiovascular safety considerations. | 2012 | Details |
| A52753 | 22428554 | J Immunotoxicol | Effects of pioglitazone and/or simvastatin on circulating TNFα and adiponectin levels in insulin resistance. | 2012 | Details |
| A52827 | 21199519 | J Gastroenterol Hepatol | Hepatic steatosis and hepatitis C: Still unhappy bedfellows? | 2011 | Details |
| A52871 | 20392876 | Mol Endocrinol | Minireview: Nuclear hormone receptor 4A signaling: implications for metabolic disease. | 2010 | Details |
| A52874 | 20361178 | Diabetologia | Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. | 2010 | Details |
| A52934 | 19349323 | Circulation | Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. | 2009 | Details |
| A52935 | 19318113 | Pharmacol Ther | Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. | 2009 | Details |
| A52979 | 18445783 | J Pharmacol Exp Ther | Age-dependent development of metabolic derangement and effects of intervention with pioglitazone in Zucker diabetic fatty rats. | 2008 | Details |
| A52990 | 18220654 | Curr Diabetes Rev | Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. | 2007 | Details |
| A52997 | 18154189 | Clin Cornerstone | Metabolic consequences of hyperglycemia and insulin resistance. | 2007 | Details |
| A53039 | 16750656 | Vascul Pharmacol | Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of type 2 diabetes: relation to dysregulated phosphatidylcholine metabolism. | 2006 | Details |
| A53055 | 16339123 | Obes Res | (+)-Z-Bisdehydrodoisynolic acid ameliorates obesity and the metabolic syndrome in female ZDF rats. | 2005 | Details |
| A53057 | 16248830 | Curr Drug Targets Cardiovasc Haematol Disord | Role of PPAR- gamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective. | 2005 | Details |
| A53064 | 16088969 | Diabetes Metab Res Rev | Prevention of nutritionally induced diabetes by rosiglitazone in the gerbil Psammomys obesus. | 2006 | Details |
| A53084 | 15297448 | Endocrinology | Small-molecule insulin mimetic reduces hyperglycemia and obesity in a nongenetic mouse model of type 2 diabetes. | 2004 | Details |
| A53085 | 15262452 | Clin Ther | A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus. | 2004 | Details |
| A53098 | 14739074 | Biochimie | Central role of the adipocyte in the insulin-sensitising and cardiovascular risk modifying actions of the thiazolidinediones. | 2003 | Details |
| A53110 | 12793594 | Int J Clin Pract Suppl | The relationship of obesity to the metabolic syndrome. | 2003 | Details |
| A53123 | 11921433 | Diabetes Metab Res Rev | The mode of action of thiazolidinediones. | 2002 | Details |
| A53124 | 11921432 | Diabetes Metab Res Rev | Insulin resistance in type 2 diabetes: role of fatty acids. | 2002 | Details |